Prognose
Analytikernes gennemsnitlige kursmål er 20,96 € (+308,58 %). Medianen er 22,78 € (+344,05 %).
| Køb |
17 |
| Behold |
2 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Ocular Therapeutix on track to submit NDA for AXPAXLI after positive pre‑NDA meeting
Ocular Therapeutix completed a positive FDA pre‑NDA meeting and plans to file the NDA for AXPAXLI in Q4 2026, supported by Week 52 SOL‑1 data and interim SOL‑R results. SOL‑1 showed superiority to aflibercept with durable vision benefits and up to 72% fewer injections over 60 weeks, and the company expects a potential 2027 launch if approved. The firm faces widening cash burn and net losses, reliance on a single marketed product for revenue, and extended SOL‑R endpoints now pushing additional topline data to Q1 2028. Market positioning is polarized with rising institutional interest but elevated short interest around 15% of the float. » Mere på finance.yahoo.com
Ocular Therapeutix stock climbs after EyePoint study failure
Ocular Therapeutix’s stock rose after it became known that EyePoint Pharmaceuticals’ phase‑3 LUGANO study of DURAVYU did not meet the primary endpoint in wet AMD. The trial failure temporarily reduces competitive pressure on Ocular’s candidate AXPAXLI, which, after a positive FDA type‑C meeting, is aiming to file an accelerated approval application (505(b)(2)) at the end of 2026. Ocular reports longer durability and favorable safety data versus aflibercept in the phase‑3 SOL‑1 study and is targeting a 2027 market launch. The stock reached an intraday high of $11.16 and later traded around $10.67. » Mere på de.investing.com
Ocular Therapeutix: FDA agrees to approval pathway for AXPAXLI based on a single study
According to a presentation at the H.C. Wainwright conference, Ocular Therapeutix has reached an agreement with the FDA to submit the full approval package for AXPAXLI based on a single study; a submission is planned for Q4 2024 and the pre-NDA meeting in Q3 2024 is expected to be purely operational. The SOL-1 data, the company says, meet masking and statistical power requirements and show a p-value <0.0006; the safety profile through week 52 is clean, with no endophthalmitis or retinal vasculitis. Ocular Therapeutix had $667 million in liquidity (end of Q1) and expects to be funded through 2028 and beyond the product launch. » Mere på de.investing.com
High options activity at Ocular Therapeutix, calls dominate trading
Options trading volume on Ocular Therapeutix rose to 9,894 contracts, of which 9,882 were calls and 12 were puts. The most heavily traded was the call expiring July 17, 2026 with a strike price of $9 (9,807 contracts); open interest stood at 10,160 contracts as of July 2. The stock fell 0.88% to $9.56, three-month volatility fell to 99.76%, and the three-month skew (90/110) rose to 10.00 percentage points. » Mere på de.investing.com
Ocular Therapeuticx advances Axpaxli regulatory plan after positive FDA Type C feedback
Ocular Therapeuticx reported favorable feedback from a Type C meeting with the FDA, prompting H.C. Wainwright to raise its price target and increase confidence in Axpaxli's approval and commercial potential. The company plans to submit a New Drug Application in Q4 2026 using SOL-1 efficacy/safety data and interim SOL-R safety results, and has revised SOL-R to collect additional endpoints through Week 96. Ocular Therapeuticx also narrowed its non‑proliferative diabetic retinopathy program to focus resources on the Phase 3 HELIOS-3 trial. » Mere på finance.yahoo.com
Virksomhedstal
I det seneste kvartal havde Ocular Therapeutix en omsætning på 11,37 mio. € og et nettoresultat på -83,68 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 11,37 mio. | 8,29 % |
| Bruttofortjeneste | 10,08 mio. | 7,36 % |
| Nettoresultat | -83,68 mio. | 41,46 % |
| EBITDA | -79,05 mio. | 41,96 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,12 mia. € |
Antal aktier | 220,02 mio. |
Højeste/laveste i 52 uger | 14,98 € - 5,05 € |
| Udbytte | Nej |
Beta | 0,99 |
P/E (PE Ratio) | -3,82 |
PEG (PEG Ratio) | 2,48 |
K/I (PB Ratio) | 2,85 |
P/S (PS Ratio) | 24,32 |
Virksomhedsprofil
Ocular Therapeutix, Inc., et biofarmaceutisk selskab, fokuserer på formulering, udvikling og kommercialisering af behandlinger for sygdomme og tilstande i øjet ved hjælp af sin bioresorberbare hydrogelbaserede formuleringsteknologi. Selskabet markedsfører ReSure Sealant, en oftalmisk medicinsk anordning til at forhindre sårlækager i hornhindeincisioner efter katarakt-operation; og DEXTENZA, en dexamethason-oftalmisk indsats til behandling af postoperativ okulær inflammation og smerte efter oftalmisk kirurgi samt allergisk konjunktivitis. Selskabet udvikler også OTX-TKI, et axitinib-intravitreal implantat, der er i fase 1 kliniske forsøg til behandling af våd aldersrelateret makuladegeneration og andre retinale sygdomme; OTX-TIC, et travoprost-intrakameralt implantat, der er i fase 2 kliniske forsøg til behandling af åbenvinkelglaukom eller okulær hypertension; OTX-CSI, en cyclosporin-intrakanalikulær indsats, der har gennemført fase 2 kliniske forsøg til behandling af tør øjesygdom; og OTX-DED, en dexamethason-intrakanalikulær indsats, der er i fase 2 kliniske forsøg til kortvarig behandling af symptomer og tegn på tør øjesygdom. Selskabet har et strategisk samarbejde med Regeneron Pharmaceuticals, Inc. (Regeneron) om udvikling og kommercialisering af produkter, der anvender selskabets vedvarende-frigivende hydrogel i kombination med Regenerons store molekyle VEGF-målrettede forbindelser til behandling af retinale sygdomme; og med AffaMed Therapeutics Limited om udvikling og kommercialisering af DEXTENZA og OTX-TIC, samt et opdagelsessamarbejde med Mosaic Biosciences om at identificere nye targets og terapeutiske midler til behandling af tør aldersrelateret makuladegeneration (dMAD). Ocular Therapeutix, Inc. blev stiftet i 2006 og har hovedkvarter i Bedford, Massachusetts.
| Navn | Ocular Therapeutix |
| CEO | Pravin U. Dugel |
| Hjemsted | Bedford,
ma USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 25.07.2014 |
| Medarbejdere | 325 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | OCUL |
Frankfurt | 0OT.F |
Düsseldorf | 0OT.DU |
SIX | 0OT.SW |